Document: Process for submitting existing data on medicinal products authorised for human use – SIAMED II & XEVMPD to PMS deltas - Chapter 9-2026/4/21

Document: Opinion of the CVMP on the establishment of maximum residue limits: Lidocaine (EMEA/V/MRL/003649/MODF/0004)-2026/4/21

Document: Guidance on the electronic submission of information on investigational medicinal products for human use in the Extended EudraVigilance medicinal product dictionary (XEVMPD)-2026/4/20

Document: Annex to agenda of the CHMP meeting 20-23 April 2026-2026/4/20

Document: Agenda of the CHMP meeting 20-23 April 2026-2026/4/20

Page: Submission dates-2026/4/20

Page: Respiratory syncytial virus (RSV)-2026/4/20

Document: Validation checklist for initial marketing authorisation applications - biologicals other than immunologicals (applicable to submissions under Regulation (EU) 2019/6)-2026/4/20

Document: Focus group on submission predictability: 2025 final report-2026/4/20

Page: Recommendations on medication errors-2026/4/16